Fig. 2.

LY354740 pretreatment attenuates amphetamine-induced increases in dopamine release and hyperlocomotion. Rats were given an IP injection of 10.0 mg/kg of LY354740 (filled circles) or 0.9% saline (open circles) 20 min prior to an injection of 1.0 mg/kg of amphetamine. Dopamine release was measured in the a DStr (LY354740 group, n=9; mean baseline dopamine=1.7±0.3 fmol/μL; saline group, n=9; mean baseline dopamine=1.1±0.3 fmol/μL) and b NAc (LY354740 group, n=9; mean baseline dopamine= 1.6± 0.3 fmol/μL; saline group, n=7; mean baseline dopamine=0.6± 0.2 fmol/μL). Locomotor activity also was measured for each animal, expressed as c fine movements (LY354740 group, n=9; saline group, n=10) or d ambulations (LY354740 group, n=9; saline group, n=10). Peak fine movements were significantly correlated to peak dopamine release in the e DStr (one outlier was omitted from the LY354740 group) and f NAc (one outlier was omitted from the LY354740 group), but peak ambulations were not significantly correlated to peak dopamine release in g and h either brain region (one outlier was omitted from each treatment group in these two graphs). In graphs A, B, C, and D, baseline dopamine release or locomotor activity is represented by the first three time points displayed. Asterisks denote significant differences between treatment groups at a given time point (* p<0.05, ** p<0.01) while plus signs indicate significant differences compared to baseline within a given treatment group (+p<0.05, ++p<0.01)